Literature DB >> 20026764

Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension.

Jeffrey S Gilbert1, Joseph Verzwyvelt, Drew Colson, Marietta Arany, S Ananth Karumanchi, Joey P Granger.   

Abstract

Antagonism of vascular endothelial growth factor (VEGF) signaling by soluble fms-like tyrosine kinase 1 occurs during preeclampsia and is proposed to play an important role in the pathogenesis of preeclampsia. We reported recently that hypertension associated with chronic reductions in uteroplacental perfusion pressure (RUPP) is associated with increased soluble fms-like tyrosine kinase 1 and decreased free VEGF. Whether restoration of circulating VEGF can restore renal function and chronically decrease arterial pressure associated with placental ischemia remains unknown. We hypothesized that chronic infusion of VEGF(121) would attenuate hypertension, increase glomerular filtration rate, and reverse the endothelial dysfunction associated with chronic RUPP. VEGF(121) (at either 90 or 180 microg/kg per day) was administered for 5 days via osmotic minipump placed IP. Mean arterial pressure, renal function, and tissues were obtained on day 19 of pregnancy from RUPP+VEGF, RUPP, and normal pregnant dams. Mean arterial pressure was increased in the RUPP (131+/-3 mm Hg) compared with the normal pregnant (102+/-1 mm Hg) rats, and infusion of VEGF(121) resolved the hypertension (105+/-5 mm Hg). Glomerular filtration rate was decreased in the RUPP dams (1.5+/-0.3 mL/min) and restored to normal pregnant levels (3.1+/-0.5 mL/min) by VEGF(121) treatment (3.1+/-0.4 mL/min). Effective renal plasma flow, decreased by RUPP, was also increased by VEGF(121) infusion. Relaxation to acetylcholine was enhanced by the VEGF treatment (P<0.05). These data demonstrate that chronic infusion of VEGF(121) during late gestation restores glomerular filtration rate and endothelial function and reduces high blood pressure associated with placental ischemia. The present results suggest that VEGF(121) may be a candidate molecule for management of preeclampsia and its related complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20026764      PMCID: PMC2824248          DOI: 10.1161/HYPERTENSIONAHA.109.141937

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  34 in total

Review 1.  Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction.

Authors:  Jeffrey S Gilbert; Michael J Ryan; Babbette B LaMarca; Mona Sedeek; Sydney R Murphy; Joey P Granger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-11-30       Impact factor: 4.733

Review 2.  Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Jeffery Gilbert; Joey P Granger
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

Review 3.  Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Michael J Ryan; Jeffrey S Gilbert; Sydney R Murphy; Joey P Granger
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

4.  Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1.

Authors:  A Makris; C Thornton; J Thompson; S Thomson; R Martin; R Ogle; R Waugh; P McKenzie; P Kirwan; A Hennessy
Journal:  Kidney Int       Date:  2007-03-21       Impact factor: 10.612

5.  Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression.

Authors:  Jeffrey S Gilbert; Sara A B Gilbert; Marietta Arany; Joey P Granger
Journal:  Hypertension       Date:  2008-12-15       Impact factor: 10.190

6.  Role of sex steroids in modulating tumor necrosis factor alpha-induced changes in vascular function and blood pressure.

Authors:  Babbette D LaMarca; Derrick L Chandler; Lee Grubbs; Jennifer Bain; Gerald R McLemore; Joey P Granger; Michael J Ryan
Journal:  Am J Hypertens       Date:  2007-11       Impact factor: 2.689

7.  Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression.

Authors:  Jeffrey S Gilbert; Sara A Babcock; Joey P Granger
Journal:  Hypertension       Date:  2007-10-08       Impact factor: 10.190

8.  Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.

Authors:  Zhihe Li; Ying Zhang; Jing Ying Ma; Ann M Kapoun; Qiming Shao; Irene Kerr; Andrew Lam; Gilbert O'Young; Frederick Sannajust; Peter Stathis; George Schreiner; S Ananth Karumanchi; Andrew A Protter; N Stephen Pollitt
Journal:  Hypertension       Date:  2007-08-27       Impact factor: 10.190

9.  Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats.

Authors:  Jason P Bridges; Jeffrey S Gilbert; Drew Colson; Sara A Gilbert; Matthew P Dukes; Michael J Ryan; Joey P Granger
Journal:  Am J Hypertens       Date:  2009-03-05       Impact factor: 2.689

Review 10.  Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections.

Authors:  Jeffrey S Gilbert; Mark J Nijland; Penny Knoblich
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-11
View more
  88 in total

1.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

2.  Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice.

Authors:  Ashley K Woods; Darren S Hoffmann; Christine J Weydert; Scott D Butler; Yi Zhou; Ram V Sharma; Robin L Davisson
Journal:  Hypertension       Date:  2010-11-15       Impact factor: 10.190

Review 3.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

4.  Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.

Authors:  Kathryn E Lillegard; Alex C Loeks-Johnson; Jonathan W Opacich; Jenna M Peterson; Ashley J Bauer; Barbara J Elmquist; Ronald R Regal; Jeffrey S Gilbert; Jean F Regal
Journal:  J Pharmacol Exp Ther       Date:  2014-08-22       Impact factor: 4.030

5.  Interleukin-17 signaling mediates cytolytic natural killer cell activation in response to placental ischemia.

Authors:  Olivia K Travis; Dakota White; Cedar Baik; Chelsea Giachelli; Willie Thompson; Cassandra Stubbs; Mallory Greer; James P Lemon; Jan Michael Williams; Denise C Cornelius
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-22       Impact factor: 3.619

6.  Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice.

Authors:  Athar H Siddiqui; Roxanna A Irani; Yujin Zhang; Yingbo Dai; Sean C Blackwell; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  Am J Hypertens       Date:  2010-12-23       Impact factor: 2.689

7.  Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Authors:  Keiichi Kumasawa; Masahito Ikawa; Hiroyasu Kidoya; Hidetoshi Hasuwa; Tomoko Saito-Fujita; Yuka Morioka; Nobuyuki Takakura; Tadashi Kimura; Masaru Okabe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 8.  Tracking placental development in health and disease.

Authors:  John D Aplin; Jenny E Myers; Kate Timms; Melissa Westwood
Journal:  Nat Rev Endocrinol       Date:  2020-06-29       Impact factor: 43.330

9.  Exercise training attenuates placental ischemia-induced hypertension and angiogenic imbalance in the rat.

Authors:  Jeffrey S Gilbert; Christopher T Banek; Ashley J Bauer; Anne Gingery; Karen Needham
Journal:  Hypertension       Date:  2012-10-22       Impact factor: 10.190

10.  A new mouse model to explore therapies for preeclampsia.

Authors:  Abdulwahab Ahmed; Jameel Singh; Ysodra Khan; Surya V Seshan; Guillermina Girardi
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.